Republicans and their allies in the business community talk a good game about the virtues of free-market competition. But, as we've seen in the debate over the public option, that stance often goes out the window when corporate profits are at stake. And now we've got another example — one of the sleaziest and most blatantly self-serving yet.
Go here to see the original:
Drug-makers paying off competitors to keep cheap generics off market
